Picard Medical Inc Dossier
|
SectorHealth Care IndustryHealth Care Equipment Beta (adjusted)1.00 Intrinsic Value $1.23median of 2 methodsbased on filings through 30 Jun 2026 Market Price $4.32Price as of 1 Oct 2026 Significantly overvaluedIntrinsic value is 72% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% marker beyond scale (-72%) Data confidence Sign in to view data confidence Market Cap $10.1M Enterprise Value $10.1M Shares Outstanding 2.3M diluted All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Picard Medical, Inc. (NYSE American: PMI) is a high-stakes medical technology company operating as the parent of SynCardia Systems, LLC, the manufacturer of the world's only FDA- and Health Canada-approved implantable Total Artificial Heart (TAH). While the company is experiencing strong commercial momentum—highlighted by an 85% year-over-year revenue increase to $1.2 million and a swing to a positive 24% gross margin in Q1 2026—it faces severe financial and regulatory headwinds. These include a going-concern qualification in its 2025 financial statements and non-compliance notices from the NYSE American regarding stockholders' equity. Although management is actively de-leveraging and simplifying its capital structure, the stock remains highly speculative, warranting a Hold recommendation until listing compliance is secured and a clear path to profitability is established. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $0.1020% The bear case materializes if the NYSE American rejects Picard's compliance plan, leading to delisting procedures and a transition to over-the-counter (OTC) trading. This outcome, compounded by an inability to raise additional capital, would stall the Emperor TAH development timeline and severely restrict liquidity, driving the stock toward its historical lows. Base CaseCentral scenario $0.0255% The base case assumes steady commercial execution with moderate revenue growth for the SynCardia TAH platform. Picard successfully submits and receives approval for its NYSE American compliance plan, avoiding delisting. However, high R&D expenses for the Emperor TAH program and ongoing capital requirements keep the company unprofitable in the near term, limiting immediate valuation upside. Bull CaseUpside scenario $1.5025% The bull case is driven by rapid commercial adoption of the SynCardia TAH, successful expansion of clinical indications (such as Destination Therapy), and the timely clinical launch of the next-generation, fully implantable Emperor TAH by 2028. Under this scenario, Picard successfully regains NYSE American listing compliance, scales manufacturing to improve gross margins toward long-term targets, and achieves self-sustaining profitability. Scenarios reflect our research view at the research date. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |